The Japan contract development and manufacturing organization market size is expected to reach USD 19.5 billion by 2030, registering a CAGR of 5.9% from 2023 to 2030, according to a new report by Grand View Research, Inc. The main drivers of this market are rising investment by contract development and manufacturing organizations (CDMOs) for capacity expansion, a high geriatric population and growing disease burden in Japan, and low costs associated with outsourcing drug manufacturing and development services.
The COVID-19 pandemic boosted the demand for the CDMO market. Several CDMOs in Japan had tried to improve their capability by expanding their facilities even during the pandemic. For instance, in August 2020, Bushu Pharmaceuticals expanded its facility in the Misato plant in Japan to be dedicated to the storage of temperature-controlled sterile drugs and biologics. Similarly, in July 2020, CMIC Group established a new facility in Japan dedicated to processing development and GMP manufacturing of antibody drugs. Such initiatives by CDMOs in the country are expected to have a positive impact on the market.
The market players are continuously engaging in major strategic initiatives like expanding their facilities, collaborating, partnerships, new service launches, and mergers & acquisitions. For instance, in May 2020, Catalent, a market leader in clinical supply services, announced plans to buy a clinical packaging facility from Teva-Takeda Pharmaceuticals, Nagoya Aichi, Japan. By making this purchase, a new clinical GMP production and distribution hub will be created to assist clinical research. Furthermore, in July 2022, Catalent announced that it would be constructing a high-speed blister packaging line in Shiga, Japan. This will be in addition to its automated fill-and-finish production facility.
Request a free sample copy or view report summary: Japan Contract Development And Manufacturing Organization Market Report
The API product segment accounted for the largest revenue share of 81.0% in 2022. The product segment is divided into API and drug product
Based on application, the commercial segment dominated with the largest revenue share of 88.0% in 2022. This is due to the rising demand for generic drugs, and the high burden of chronic diseases are some factors contributing to the growth
The oncology segment is anticipated to register the fastest CAGR of 6.4% during the forecast period, due to the growing number of cancer cases in the country which is improving the demand for new cancer therapeutics
In November 2020, WuXi AppTec expanded its services offered by Cell & Gene Therapy Platform. The platform is now capable of developing, manufacturing, and introducing cell and gene therapies faster and with greater predictability
Grand View Research has segmented the Japan contract development and manufacturing organization market on the basis of product, workflow, and application:
Japan CDMO Product Outlook (Revenue, USD Million, 2018 - 2030)
Traditional Active Pharmaceutical Ingredient (Traditional API)
Highly Potent Active Pharmaceutical Ingredient (HP-API)
Antibody Drug Conjugate (ADC)
Oral Solid Dose
Japan CDMO Workflow Outlook (Revenue, USD Million, 2018 - 2030)
Japan CDMO Application Outlook (Revenue, USD Million, 2018 - 2030)
List of Key Players in the Japan Contract Development And Manufacturing Organization (CDMO) Market
Laboratory Corporation of America Holdings
Thermo Fisher Scientific, Inc.
Sumitomo Chemical Company, Limited
CMIC HOLDINGS Co., LTD.
Bushu Pharmaceuticals Ltd.
GET A FREE SAMPLE
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
"The quality of research they have done for us has been excellent..."